Health Canada’s modernization of clinical trial regulations is changing how new medical technologies enter practice. The move toward risk‑proportionate oversight means that low‑risk or early‑stage trials can proceed with processes scaled to their complexity. This shift opens the door for smaller research teams and founder‑led companies to test innovations sooner, often in partnership with community clinics or regional health networks rather than large hospital centres. The ch
